This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 30, 2012 9:00 am ET
Charles Randal Mills - Chief Executive Officer, President and Director
Philip R. Jacoby - Chief Financial Officer, Treasurer and Corporate Secretary
Edward A. Tenthoff - Piper Jaffray Companies, Research Division
Eun K. Yang - Jefferies & Company, Inc., Research Division
Good morning, everyone. Welcome to the Osiris Therapeutics Second Quarter and Full Year 2012 Earnings Conference Call.
Before we would begin, I would like to remind everyone that this conference may include forward-looking statements that involve uncertainties and risks. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled Risk Factors in our filings with the Securities and Exchange Commission.
As a reminder, today's call is being recorded.
I would now like turn the conference over to Dr. C. Randal Mills, President and CEO of Osiris Therapeutics. Please go ahead, sir.
Charles Randal Mills
Thank you. Good morning. Thank you for joining us for our second quarter 2012 conference call. Today, I'd like to provide you with an update on Prochymal, our intravenous stem cell therapy, which made history in the second quarter by becoming the world's first stem cell drug approved by an internationally recognized regulatory agency. I will then discuss the exciting momentum we are gaining in our Biosurgery division. Phil Jacoby, our Chief Financial Officer will provide you with an update of our financial performance over the last quarter. And in closing, I will offer a few comments before turning the call over to the operator for questions.